The development of NECT is the result of a collaborative partnership over a period of six years between DNDi, Médecins Sans Frontières, Epicentre, the HAT platform, the Swiss Tropical & Public Health Institute (Swiss TPH), the National Control Programmes of the Democratic Republic of the Congo (DRC) and Republic of Congo, with the support of the World Health Organization (WHO), with drugs donated by Sanofi and Bayer Schering Pharma AG.


Thanks to continuous support from public and private donors, DNDi was able to provide 4.6 million Euros (€) in support of the clinical research phase, including 1 million € from the HAT Platform and 1.6 million € from the European Union (EU) as well as the support from:
  • The Ministry of Foreign and European Affairs (MAEE) – France
  • The Spanish Agency of International Cooperation for Development (AECID) – Spain
  • The Department for International Development (DFID) – United Kingdom
  • Médecins Sans Frontières (Doctors Without Borders)
  • The Medicor Foundation – Liechtenstein
  • The European Union – Framework Programme 5 and 6